US 12,168,681 B2
Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
Jiaxi Wu, Pleasantville, NY (US); Tong Zhang, New Rochelle, NY (US); Samuel Davis, New York, NY (US); and Nicolin Bloch, Ossining, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 25, 2023, as Appl. No. 18/494,355.
Application 18/494,355 is a division of application No. 17/234,896, filed on Apr. 20, 2021, granted, now 11,834,485.
Claims priority of provisional application 63/167,188, filed on Mar. 29, 2021.
Claims priority of provisional application 63/013,058, filed on Apr. 21, 2020.
Prior Publication US 2024/0067690 A1, Feb. 29, 2024
Int. Cl. C07K 14/55 (2006.01); A61K 38/00 (2006.01); A61K 38/20 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01); C07K 14/735 (2006.01); C07K 14/74 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 38/2013 (2013.01); A61K 45/06 (2013.01); C07K 14/4748 (2013.01); C07K 14/70535 (2013.01); C07K 14/70539 (2013.01); A61K 38/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/41 (2013.01)] 5 Claims
 
1. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes an isolated interleukin-2 (IL-2) variant comprising the polypeptide sequence as set forth in SEQ ID NO: 4.